NasdaqGS - Delayed Quote • USD
Crinetics Pharmaceuticals, Inc. (CRNX)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 5:38 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 12 |
| Avg. Estimate | -0.86 | -0.87 | -3.55 | -3.81 |
| Low Estimate | -1.06 | -1.11 | -4.25 | -5.06 |
| High Estimate | -0.69 | -0.77 | -3.19 | -2.94 |
| Year Ago EPS | -0.94 | -1.01 | -3.69 | -3.55 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 11 | 11 |
| Avg. Estimate | 460k | 180k | 2.09M | 14.13M |
| Low Estimate | -- | -- | 600k | 3M |
| High Estimate | 2.5M | 1M | 5.6M | 58M |
| Year Ago Sales | 988k | 120k | 4.01M | 2.09M |
| Sales Growth (year/est) | -53.40% | 50.00% | -47.90% | 576.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.86 | -0.86 | -0.86 | -0.81 |
| EPS Actual | -0.94 | -1.01 | -0.9 | -0.93 |
| Difference | -0.08 | -0.15 | -0.04 | -0.12 |
| Surprise % | -9.30% | -17.40% | -4.70% | -14.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.86 | -0.87 | -3.55 | -3.81 |
| 7 Days Ago | -0.86 | -0.87 | -3.55 | -3.81 |
| 30 Days Ago | -0.79 | -0.83 | -3.31 | -3.64 |
| 60 Days Ago | -0.8 | -0.84 | -3.29 | -3.54 |
| 90 Days Ago | -0.79 | -0.82 | -3.26 | -3.5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRNX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.50% | -- | -- | 9.10% |
| Next Qtr. | 13.90% | -- | -- | 11.50% |
| Current Year | 3.80% | -- | -- | 5.70% |
| Next Year | -7.30% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 6/4/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 6/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/4/2024 |
| Maintains | Baird: Outperform to Outperform | 5/23/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 5/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/23/2024 |
Related Tickers
MLTX MoonLake Immunotherapeutics
41.67
-1.81%
MRUS Merus N.V.
52.90
-1.51%
IDYA IDEAYA Biosciences, Inc.
38.01
-4.09%
APGE Apogee Therapeutics, Inc.
41.69
-1.01%
CYTK Cytokinetics, Incorporated
52.79
+0.98%
FDMT 4D Molecular Therapeutics, Inc.
22.72
+0.66%
NUVL Nuvalent, Inc.
79.18
-2.98%
JANX Janux Therapeutics, Inc.
44.16
+3.69%
REPL Replimune Group, Inc.
7.90
+11.11%
ACLX Arcellx, Inc.
50.78
-1.09%